Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Shingles vaccination may lower risk of severe COVID-19, study finds 

By Brian Buntz | January 4, 2022

Vaccine stock art

Image courtesy of Pixabay

A large retrospective study found that a recombinant adjuvanted zoster vaccine was associated with a 32% reduced risk of COVID-19-associated hospitalization. The study, published in The Journal of Infectious Diseases, also found that individuals who received at least one dose of the Shingrix vaccine were 16% less likely to be diagnosed with COVID-19 during the trial period. The study authors concluded that the Shingrix vaccine offered a durable reduction in COVID-19 risk. 

The study was conducted by GSK (NYSE:GSK) and Kaiser Permanente Southern California (KPSC). Recruiting individuals at least 50 from 1 March 2020 to 31 December 2020, the study followed 149,244 Shingrix zoster vaccine recipients and 298,488 unvaccinated individuals. 

The study authors concede that the analysis had limitations related to variable health status and adherence to COVID-19 protocols such as mask-wearing, social distancing and other protective measures. 

Other studies support the hypothesis that some vaccines may boost immunity broadly, priming it to battle other pathogens. For instance, in the 1960s and 1970s, researchers in the Soviet Union found that the oral polio vaccine appeared to reduce mortality from the flu, as The New York Times reported.  

Earlier studies have also found that vaccines for flu, measles and Bacillus Calmette-Guérin (BCG) also seem to ramp up the immune system, improving protection against heterologous infections.

That said, COVID-19 vaccines continue to play a vital role in reducing the risk of severe disease. 


Filed Under: Infectious Disease
Tagged With: covid-19, GSK, Kaiser Permanente, recombinant adjuvanted zoster vaccine, shingles, Shingrix
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Skycovion
European authorities begin review of Skycovion COVID-19 vaccine candidate
Pfizer-BioNTech vaccine
U.S. government plans to stop paying for COVID-19 vaccines 
Monkeypox
U.S. to boost supplies of Tpoxx to fight monkeypox outbreak
Pfizer-BioNTech
Next-gen Pfizer-BioNTech vaccine candidates fare well in Phase 2/3 study

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50